The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Sickle Cell Disease Treatment Market Expected To Change From 2026 To 2030?
The sickle cell disease treatment market size has seen swift expansion in recent years. It is forecast to grow from $3.51 billion in 2025 to $4.11 billion in 2026, achieving a compound annual growth rate (CAGR) of 17.3%. Historically, this growth can be attributed to the significant prevalence of the disease in Africa and the Americas, limited availability of treatments, reliance on blood transfusions, progress in hematology research, and a lack of awareness regarding early diagnosis.
The sickle cell disease treatment market is projected for substantial expansion over the coming years. This market is set to reach $7.99 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 18.1%. This anticipated growth is largely driven by factors such as the emergence of gene therapy solutions, the broadening availability of biologics and targeted drugs, the incorporation of predictive diagnostics, a rise in global healthcare initiatives, and the development of personalized treatment plans for patients. Key trends anticipated during this period encompass the development of gene-editing therapies, an uptick in the availability of hydroxyurea, an expansion of blood transfusion management practices, the implementation of advanced diagnostics for earlier detection, and the proliferation of patient support and disease management programs.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13048&type=smp
Which Important Drivers Are Guiding The Sickle Cell Disease Treatment Market Growth?
An increase in blood and bone marrow transplants is anticipated to drive the future expansion of the sickle cell disease treatment market. This medical procedure involves substituting unhealthy blood-producing cells with healthy counterparts. The objective of a bone marrow transplant is to treat sickle cell diseases and certain cancers by introducing healthy bone marrow cells into an individual subsequent to the removal of abnormal cells from their diseased bone marrow. These replacement cells can originate either from the patient’s own body, known as an autologous transplant, or from a donor, referred to as an allogeneic transplant. As an illustration, in June 2024, data from the National Transplant Organization (ONT), an independent coordinating agency based in Spain, indicated that in 2023, Spain enrolled 23,686 new donors into its Bone Marrow Donor Registry, marking an 8% rise compared to 2022. Furthermore, the country accomplished a record 3,717 hematopoietic stem cell transplants, which corresponds to 77.4 transplants per million inhabitants. Consequently, the growing prevalence of blood and bone marrow transplants is set to stimulate the sickle cell disease treatment market.
How Is The Sickle Cell Disease Treatment Market Organized By Segment Classification?
The sickle cell disease treatment market covered in this report is segmented –
1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant
2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types
3) By Route Of Administration: Oral, Parenteral
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion
2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab
3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant
What Trends Are Influencing The Evolution Of The Sickle Cell Disease Treatment Market?
Leading firms within the sickle cell disease treatment market are prioritizing the creation of novel oral suspension medications, with the goal of boosting patient adherence, strengthening medication effectiveness, and offering more accessible treatment choices, especially for younger and older patients. Oral suspensions consist of liquid-based drugs containing solid particles, formulated to facilitate easier ingestion for individuals, particularly children or those encountering difficulty with tablet forms. An example is observed in March 2024, when Akums Drugs and Pharmaceuticals Ltd., a pharmaceutical preparation manufacturer based in India, introduced a Hydroxyurea oral suspension that maintains stability at room temperature. This specific medication for SCD presents an economical and room-temperature-stable therapeutic option, intended to broaden access across India. Available at less than 1% of the cost of imported alternatives, it allows for accurate dosage delivery via oral syringes, proving advantageous for patients across all age groups and eliminating the need for refrigeration.
Who Are The Industry Participants Involved In The Sickle Cell Disease Treatment Market?
Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Mast Therapeutics Inc.
Get The Full Sickle Cell Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report
Which Region Dominates The Sickle Cell Disease Treatment Market By Market Share?
North America was the largest region in the sickle cell disease treatment market in 2025. The regions covered in the sickle cell disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Sickle Cell Disease Treatment Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/sickle-cell-disease-treatment-global-market-report
Browse Through More Reports Similar to the Global Sickle Cell Disease Treatment Market 2026, By The Business Research Company
Cells Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cells-therapy-global-market-report
Rare Diseases Treatment Market Report
https://www.thebusinessresearchcompany.com/report/rare-diseases-treatment-global-market-report
Cell Therapy Technologies Market Report
https://www.thebusinessresearchcompany.com/report/cell-therapy-technologies-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model